Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Ehave
(OTCEM:EHVVF)
Intraday
$0.001
0
[0.00%]
15 minutes delayed
Get Report
Watch
Perks
Buy
Compare Brokers
$0.001
0
[0.00%]
Last update: 3:56PM
Get Real Time Here
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Ehave Stock (OTC:EHVVF)
Ehave Stock (OTC: EHVVF)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, February 03, 2023
Combatting The 'Bad Trip': New Research Project Seeks Solutions That Go Beyond Psychedelics
Jelena Martinovic
-
Feb 3, 2023, 12:45PM
Friday, December 16, 2022
FDA Green Lights New Study Testing IV Ketamine Infusion For Depressive Disorder
Lara Goldstein
-
Dec 16, 2022, 5:03PM
Wednesday, June 08, 2022
Psyched: Christie's Launches NFT Collection Supporting Psychedelic Science, Origin's Listing On CSE Gives Retail Investors Access To Private Companies
Natan Ponieman
-
Jun 8, 2022, 8:45AM
Wednesday, June 01, 2022
Ehave Partners With Halugen Life Sciences To Create A Ketamine Precision Medicine Platform For Clinical Research
Lara Goldstein
-
Jun 1, 2022, 4:30PM
Monday, May 23, 2022
Ehave's Mycotopia Therapies To Merge With Ei.Ventures To Form PSLY.COM
Vuk Zdinjak
-
May 23, 2022, 11:43AM
Tuesday, February 22, 2022
Psyched: Psilocybin Therapy Effective After One Year, Cybin & Deepak Chopra, Enveric Psilocybin Cancer Study
Natan Ponieman
-
Feb 22, 2022, 12:29PM
Tuesday, February 15, 2022
KetaDASH Announces Mobile Ketamine Treatments in San Francisco and Sacramento Area
Nicolas Jose Rodriguez
-
Feb 15, 2022, 3:28PM
Monday, October 18, 2021
Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
Natan Ponieman
-
Oct 18, 2021, 1:37PM
Wednesday, October 13, 2021
There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are
Natan Ponieman
-
Oct 13, 2021, 4:25PM
Saturday, September 25, 2021
Cannabis Movers & Shakers: Greenlight Distribution, Petalfast, Tinley Beverage, Shryne Group, Ehave, NY Cannabis Control Board
Jelena Martinovic
-
Sep 25, 2021, 9:15PM
Monday, December 28, 2020
2020 Was The Year of Psychedelics — Here's Why
Natan Ponieman
-
Dec 28, 2020, 9:02AM
Saturday, December 19, 2020
Psyched: MDMA On Health Canada's Radar, MindMed Seeks FDA Support For LSD, Numinus Buys Mindspace
Natan Ponieman
-
Dec 19, 2020, 9:30AM
Tuesday, June 30, 2020
Digital Therapeutics Field Is Fast On The Rise, Ehave Is Advancing Research In Psychedelics And ADHD Therapy
Jaycee Tenn
-
Jun 30, 2020, 9:27AM
Saturday, June 06, 2020
'Psyched': New Leaf Brands Changes Name To Mydecine, Numinus Debuts On TSXV, MindMed To Research MDMA-LSD Interactions
Natan Ponieman
-
Jun 6, 2020, 3:15PM
Saturday, May 23, 2020
'Psyched': Mota Buys German Psilocybin Producer, Champignon Announces New CEO, $10M In Funding
Natan Ponieman
-
May 23, 2020, 3:32PM
